FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
Season 7, Episode 18, Jul 28, 2022, 08:19 PM
Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.